Stimulants that are used to treat attentiondeficit/hyperactivity disorder (ADHD) will have stronger warning labels, according to an FDA mandate. The labels will warn against the use of the medications in adults or children with heart problems and will notify physicians that they can cause 1 child in 1000 to experience hallucinations. The warnings will be found on Adderall (Shire Pharmaceuticals Group), Concerta (McNeil Pharmaceuticals), and Ritalin (Novartis).
Although these warnings are not as strong as those approved earlier this year by an FDA advisory committee, they significantly strengthen the risk information already on the labels. The warnings are a result of reports of sudden death in children taking the drugs. In some reports, the children were later determined to have had structural defects of the heart. The new warnings will include, in part, "Sudden deaths, strokes, and myocardial infarction have been reported in adults taking stimulant drugs at usual doses."
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs